HIV-1

Vela Diagnostics Collaborates with SRL Inc. for Product Distribution in Japan

Retrieved on: 
Lunedì, Ottobre 2, 2023
RCA, Information Holdings Inc., Partnership, HIV, HIV-1, NGS, Research and development, Drug resistance, Patient, VELA, FDA, Massive parallel sequencing, Medical device, Nursing, Research

This partnership aims to facilitate the distribution of Vela Diagnostics' cutting-edge molecular diagnostic solutions in Japan.

Key Points: 
  • This partnership aims to facilitate the distribution of Vela Diagnostics' cutting-edge molecular diagnostic solutions in Japan.
  • The research collaboration agreement (RCA) between Vela Diagnostics and SRL Inc was signed in June 2023, marking a significant milestone in their shared commitments to advancing healthcare solutions in Japan.
  • Vela Diagnostics aims to capitalize on SRL Inc's comprehensive distribution network and market understanding, enabling the company to introduce its Sentosa® SQ HIV-1 Genotyping Assay Kit to Japanese healthcare and diagnostic institutions.
  • Dr Tony Zhang, Head of Research and Development at Vela Diagnostics, states that SRL Inc has begun feasibility studies for the Sentosa® SQ HIV-1 Genotyping Assay Kit.

Vela Diagnostics Collaborates with SRL Inc. for Product Distribution in Japan

Retrieved on: 
Lunedì, Ottobre 2, 2023
RCA, Information Holdings Inc., Partnership, HIV, HIV-1, NGS, Research and development, Drug resistance, Patient, VELA, FDA, Massive parallel sequencing, Medical device, Nursing, Research

This partnership aims to facilitate the distribution of Vela Diagnostics' cutting-edge molecular diagnostic solutions in Japan.

Key Points: 
  • This partnership aims to facilitate the distribution of Vela Diagnostics' cutting-edge molecular diagnostic solutions in Japan.
  • The research collaboration agreement (RCA) between Vela Diagnostics and SRL Inc was signed in June 2023, marking a significant milestone in their shared commitments to advancing healthcare solutions in Japan.
  • Vela Diagnostics aims to capitalize on SRL Inc's comprehensive distribution network and market understanding, enabling the company to introduce its Sentosa® SQ HIV-1 Genotyping Assay Kit to Japanese healthcare and diagnostic institutions.
  • Dr Tony Zhang, Head of Research and Development at Vela Diagnostics, states that SRL Inc has begun feasibility studies for the Sentosa® SQ HIV-1 Genotyping Assay Kit.

Aspira Women’s Health Announces Dr. Jody Berry as New Chief Scientific Officer

Retrieved on: 
Lunedì, Settembre 11, 2023
Department of Medical Microbiology (Schering AG), Abstract, Pelvic inflammatory disease, Bachelor of Science, University, Apotex, Medical microbiology, HIV, Cangene, HIV-1, Head, Monoclonal antibody, Public Health Agency of Canada, COVID-19, Woman, CIHR, Infection, Research, Lehigh University, American Biological Safety Association, National Microbiology Laboratory, University of Manitoba, Government, Immunochemistry, Chlamydia trachomatis, Philosophy, Outline, Gynaecology, Blood, Scripps Research, Protein engineering, R, Public Health Agency, G.H. Raisoni Department of Microbiology and Biotechnology, University Arena (Western Michigan University), Vaccine, Science, Chlamydia, Molecular biology, Aspira

AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer.

Key Points: 
  • AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer.
  • Dr. Berry is a seasoned scientific leader with over two decades of commercial, government and academic experience.
  • Jody is a dynamic leader with decades of experience launching disruptive products and building effective research and development teams,” said Nicole Sandford, Chief Executive Officer of Aspira.
  • Dr. Berry is author or co-author on over 100 peer-reviewed published journal articles, abstracts, scientific posters, and monographs.

Uvax Bio Appoints Pedro Garbes, MD., as Vice President, Global Medical Lead

Retrieved on: 
Mercoledì, Settembre 13, 2023
Science, Biotechnology, Research, Pharmaceutical, AIDS, Health, Infectious Diseases, Clinical Trials, Vaccine, GSK plc, University, Senior, HIV, Bio, FISU World University Games, HIV-1, Allergan, COVID-19, Infection, Global health, AstraZeneca, Messenger, Administration, Sanofi Pasteur, Faculdade de Medicina da Universidade Federal de Minas Gerais, Gritstone bio, VLP, Rest, Virus, Master, Medicine

Uvax Bio LLC, a vaccine biotechnology company that utilizes its proprietary 1c-SApNP® vaccine design and manufacturing platform to produce protein-based VLP vaccines to fight viruses that threaten global health, announced today that Pedro Garbes, MD., has joined the company as Vice President, Global Medical Lead.

Key Points: 
  • Uvax Bio LLC, a vaccine biotechnology company that utilizes its proprietary 1c-SApNP® vaccine design and manufacturing platform to produce protein-based VLP vaccines to fight viruses that threaten global health, announced today that Pedro Garbes, MD., has joined the company as Vice President, Global Medical Lead.
  • Dr. Garbes joins Uvax Bio at a key inflection point as the company’s recombinant protein nanoparticle vaccines are advancing in development.
  • "We are pleased to have Pedro join our leadership team as we prepare to take our lead vaccines to the next stage of development.
  • Pedro Garbes brings to Uvax Bio over two decades of life sciences experience in clinical vaccine development, medical affairs, and medical/commercial strategy.

Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results

Retrieved on: 
Lunedì, Agosto 14, 2023
Immortalised cell line, Infection, Insurance, Partnership, HIV, HIV-1, Enzyme, GV (company), Melinda French Gates, Bill & Melinda Gates Foundation, Philips, Publishing, Novartis, Patient, Investment, Manuscript, CBO, Drug discovery, Bill, CFO, Merck, AI, Research, Pharmaceutical industry, Fine chemical, Management, California Institute of Technology

VANCOUVER, Wash. and NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today reported financial and operating results for the quarter ended June 30, 2023.

Key Points: 
  • Research and development expenses were $12.1 million for the second quarter of 2023 compared to $16.2 million for the corresponding prior year period.
  • Selling, general, and administrative expenses were $9.4 million for the second quarter of 2023 compared to $10.5 million for the corresponding prior year period.
  • Net loss was $41.7 million for the second quarter of 2023, as compared to $28.7 million for the corresponding prior year period.
  • This increase was attributable to the Company recording a non-cash goodwill impairment charge of $21.3 million within operating expenses during the second quarter of 2023.

Absci and Caltech Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development

Retrieved on: 
Giovedì, Agosto 10, 2023
Infection, Partnership, The, Life, HIV, HIV-1, Hope, Global health, Research, Melinda French Gates, Synthetic biology, Bill & Melinda Gates Foundation, AIDS, Chemistry, Bill, Pharmaceutical industry, California Institute of Technology, Biology

The grant supports the joint effort of Caltech and Absci to discover affordable HIV therapeutic vaccinations, with the goal of making a significant step forward in the fight against the global HIV/AIDS epidemic.

Key Points: 
  • The grant supports the joint effort of Caltech and Absci to discover affordable HIV therapeutic vaccinations, with the goal of making a significant step forward in the fight against the global HIV/AIDS epidemic.
  • More than 40 years after the AIDS pandemic began, there is no vaccine or cure for HIV.
  • Combining the latest advances and expertise across their respective fields, Caltech and Absci aim to confront a challenge facing millions worldwide.
  • "We are honored to be partnering with Caltech on this critical project," stated Sean McClain, Founder and CEO of Absci.

New Community Partnership Model Boosts Participant Inclusion into HIV Cure-Directed Research

Retrieved on: 
Martedì, Agosto 8, 2023
Partnership, Cell biology, University, CAB, DATE, HIV, National Institute of Mental Health, Culture, HIV-1, Policy, Infection, Cancer, Stroke, Mental health, Biomedical Research, Community advisory board, University of California, San Diego, Research, History, CEG, Person, The Philadelphia Foundation, Organization, National Institute of Neurological Disorders and Stroke, DSM-IV codes, Community, Trust, AIDS, Patient, Wistar Institute, National Institute on Drug Abuse, United States Military HIV Research Program, Montaner, Team, National Institute of Allergy and Infectious Diseases, Pharmaceutical industry, Medical device, Engagement, Wistar

Now, researchers from The Wistar Institute are sharing how a more inclusive model for community engagement can lead to deeper insights and greater community participation in HIV research.

Key Points: 
  • Now, researchers from The Wistar Institute are sharing how a more inclusive model for community engagement can lead to deeper insights and greater community participation in HIV research.
  • The community engagement group, or CEG model, is composed of a three-part structure with a Community Advisory Board (CAB), Community nonprofit organization, and researchers.
  • , vice president for scientific operations, Herbert Kean, M.D., Family Professor , director, HIV-1 Immunopathogenesis Laboratory, and leader, HIV Research Program , Vaccine & Immunotherapy Center at The Wistar Institute.
  • Publication information: “Community engagement group model in basic and biomedical research: lessons learned from the BEAT-HIV Delaney Collaboratory towards an HIV-1 cure,” Research Involvement and Engagement (DATE).

Clinical Results of ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection Presented at the 12th IAS Conference on HIV Science

Retrieved on: 
Martedì, Luglio 25, 2023
Combination, Science, DNA, International, HIV, BIW, Infection, HIV-1, Clinical trial, ART, Cell, RNA, CD8, Plasma, Death, Public health, HKEX, AIDS, MD, Patient, Blood, FACT, IAS, PD-1, PD-L1, Conference, UNAIDS, Vaccine, Tucidinostat, Immunity

The objective of this study is to evaluate the efficacy of ASC22 (Envafolimab) combined with Chidamide on the viral reservoirs of latently infected cells in HIV-infected people.

Key Points: 
  • The objective of this study is to evaluate the efficacy of ASC22 (Envafolimab) combined with Chidamide on the viral reservoirs of latently infected cells in HIV-infected people.
  • Ascletis BioScience Co., Ltd., a wholly-owned subsidiary of Ascletis, provided ASC22 (Envafolimab) for the clinical trial.
  • This Phase II study showed that combination treatment with ASC22 and Chidamide is well tolerated and effectively activated latent HIV reservoirs.
  • We are excited that ASC22 in combination of Chidamide effectively activated the latent HIV reservoirs.

Excision BioTherapeutics Receives FDA Fast Track Designation for EBT-101, a First-in-Class CRISPR-Based Gene Therapy Candidate to Functionally Cure HIV-1

Retrieved on: 
Giovedì, Luglio 20, 2023
CRISPR, US Foods, HIV, HIV-1, ART, Fast Track, Protalix BioTherapeutics, Genome, Social stigma, Risk, SAN, FDA, Food, Safety, Disease, Pharmaceutical industry

Fast Track designation is intended to facilitate the development and expedite the review of potentially important new drugs to treat serious conditions with unmet medical needs.

Key Points: 
  • Fast Track designation is intended to facilitate the development and expedite the review of potentially important new drugs to treat serious conditions with unmet medical needs.
  • Therapies granted this designation are given the opportunity for more frequent interactions with the FDA and may qualify for other designations including accelerated approval and priority review.
  • Daniel Dornbusch, Chief Executive Officer of Excision, said, “We are pleased with the FDA’s decision to grant Fast Track designation to EBT-101.
  • Without a cure, the current standard of care is antiretroviral therapy (ART) that must be taken for the duration of an individual's life.

New Study Highlights the Complexity of Using Antiviral Drug Combinations for HIV Prevention

Retrieved on: 
Mercoledì, Aprile 5, 2023
Tissue, Emtricitabine, Mouse, Human, HIV, HIV-1, National Institute of Allergy and Infectious Diseases, TDF, Biomedical Research, Woman, Viral, Physiology, Bangladesh Technical Education Board, Acquisition, FTC, Drug combination, Adolescence, Biology, Gel, Research, FDA, Infection, Vaccine

One promising approach involves delivering antiviral compounds vaginally, using inserts, gels, films, or intravaginal rings.

Key Points: 
  • One promising approach involves delivering antiviral compounds vaginally, using inserts, gels, films, or intravaginal rings.
  • They used a mathematical model to empirically study the effects of administering different doses of antiviral drugs.
  • This study provides a translational template for the preclinical evaluation of drug combinations for the prevention of HIV-1 and other viral diseases.
  • The interaction between drugs that are effective when used alone but may interfere with each other when combined highlights the complexity of predicting the effects of drug use in HIV prevention.